Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
anti-TRAIL-R3 (human), mAb (TR3.06)
460
CHF
CHF 460.00
In stock
AG-20B-0029-C100100 µgCHF 460.00
Figure 1: Immunohistochemistry detection of endogenous TRAIL-R3 in paraffin-embedded human carcinoma tissues (colon, tonsil) using mAb to TRAIL-R3 (TR3.06) (Prod. No. AG-20B-0029).
Figure 2: Negative control.
| Product Details | |
|---|---|
| Synonyms | TRAIL Receptor 3; DcR1; TRID; TNFRSF10C; CD263 |
| Product Type | Monoclonal Antibody |
| Properties | |
| Clone | TR3.06 |
| Isotype | Mouse IgG1 |
| Source/Host | Purified from concentrated hybridoma tissue culture supernatant. |
| Immunogen/Antigen | Recombinant human TRAIL-R3 (DcR1). |
| Application |
Flow Cytometry |
| Crossreactivity | Human |
| Specificity |
Recognizes human TRAIL-R3. Does not cross-react with human TRAIL-R1, -R2 or -R4. |
| Purity | ≥95% (SDS-PAGE) |
| Purity Detail | Protein G-affinity purified. |
| Concentration | 1mg/ml |
| Formulation | Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. |
| Isotype Negative Control | |
| Other Product Data |
Specially developed for the immunohistochemical detection of TRAIL-R3 in paraffin embedded tissue. Has been shown to detect TRAIL-R3 expressed at endogenous levels in paraffin-embedded tissue in different mammary carcinoma tissues. |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| Protocols |
 Download PDF |
| MSDS |
Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- TRAIL-R3 is a receptor for the cytotoxic ligand TRAIL. It lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.
Product References
- Troglitazone-mediated sensitization to TRAILinduced apoptosis is regulated by proteasomedependent degradation of FLIP and ERK1/2- dependent phosphorylation of BAD: K. Grund, et al.; Cancer Biol. Ther. 7, 1982 (2008)
- Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer: T. M. Ganten, et al.; J. Mol. Med. 87, 995 (2009)
- Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer: S. Macher-Goeppinger, et al.; Clin. Cancer Res. 15, 650 (2009)
- Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma: R. Koschny, et al.; BMC Cancer 13, 532 (2013)
- IAPs cause resistance to TRAIL-dependent apoptosis in follicular 1 thyroid cancer: T.A. Werner, et al.; Endocr. Relat. Cancer 17, 0479 (2018)
Related Products
